Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
The COVID-19 pandemic has prompted an international effort to develop and repurpose medications and procedures to effectively combat the disease. Several groups have focused on the potential treatment utility of angiotensin-converting-enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs...
Autores principales: | Bertsimas, D, Borenstein, A, Mingardi, L, Nohadani, O, Orfanoudaki, A, Stellato, B, Wiberg, H, Sarin, P, Varelmann, DJ, Estrada, V, Macaya, C, Gil, IJN |
---|---|
Formato: | Journal article |
Lenguaje: | English |
Publicado: |
Springer Nature
2021
|
Ejemplares similares
-
Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021) -
Effect of ACEi and ARBs vs Non ACEi/ARBs in Hypertension with Respect to Renal Outcomes in COVID-19 Infection: A Retrospective Cohort Study
por: S Ravitej, et al.
Publicado: (2022-11-01) -
Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
por: Jing Ma, et al.
Publicado: (2021-05-01) -
ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet AS, et al.
Publicado: (2020-09-01) -
The Potential Role of ACEi and ARBs in COVID-19; A Perspective
por: Ahmad Hammad Hassan
Publicado: (2020-12-01)